Chest
Clinical CommentaryThe Current Treatment of Pulmonary Arterial Hypertension: Time to Redefine Success
Section snippets
The Natural History of PAH
The natural history of untreated idiopathic PAH (IPAH) was well-characterized by the National Institutes of Health Registry on Primary Pulmonary Hypertension1 as it was conducted in an era when therapy largely consisted of diuretics and supplemental oxygen. Patients with PAH present with dyspnea with effort, limited exercise capacity, and signs and symptoms that were consistent with right heart failure. On cardiac catheterization, these patients uniformly will have a markedly elevated pulmonary
Is Pulmonary Arterial Hypertension Reversible?
To ascertain a realistic end point in therapeutic trials, we need to determine what type of treatment effect is possible. The obvious question becomes whether the disease is indeed reversible, and/or whether there is a certain stage at which the potential for reversibility becomes lost.
The experience with calcium channel blockers for the treatment of PAH holds some insights. The long-term effectiveness of calcium channel blocker therapy relates to a select group of patients with PAH whose
What Have We Achieved With Approved Therapies?
In the past 10 years, there have been three classes of drugs that have become approved by the regulatory authorities as a treatment of PAH. They include the prostanoids,10, 11, 12, 13 the endothelin receptor antagonists,14 and the phosphodiesterase-5 inhibitors.15 However, these therapies were approved not because they lowered pulmonary artery pressure, but because they allowed patients to perform better on a 6-min walk test, which was the primary end point in the trials. It is valid to ask
How Should We Evaluate the Treatments of PAH?
IV epoprostenol therapy has been studied considerably following its approval in 1995. There is little doubt that it produces long-term beneficial effects in patients with advanced PAH, yet its mechanism of action remains a mystery. It has been characterized as a vasodilator,20, 21 an inotrope,22 an anticoagulant,23 and a growth factor inhibitor,24 but there are no histopathologic data on how it affects the pulmonary vasculature in humans with PAH. By comparison, we know even less about the
References (42)
- et al.
Inotropic therapy for heart failure: an evidence-based approach
Am Heart J
(2001) - et al.
Hemodynamic unloading leads to regression of pulmonary vascular disease in rats
J Thorac Cardiovasc Surg
(2001) - et al.
Prevalence and mortality rate of congestive heart failure in the United States
J Am Coll Cardiol
(1992) - et al.
Beraprost therapy for pulmonary arterial hypertension
J Am Coll Cardiol
(2003) - et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
Chest
(2004) - et al.
Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension
Chest
(1989) - et al.
The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
J Am Coll Cardiol
(1999) - et al.
Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension
Chest
(2004) - et al.
Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension
Am J Cardiol
(2006) - et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study
Lancet
(2001)
Primary pulmonary hypertension: a national prospective study
Ann Intern Med
Survival in patients with primary pulmonary hypertension: results from a national prospective registry
Ann Intern Med
High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
Circulation
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
N Engl J Med
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
Circulation
Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation
J Heart Lung Transplant
Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery
J Thorac Cardiovasc Surg
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
N Engl J Med
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease
Ann Intern Med
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
Am J Respir Crit Care Med
Inhaled iloprost for severe pulmonary hypertension
N Engl J Med
Cited by (0)
Dr. Rich is also a part-time salaried consultant to United Therapeutics Corporation.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).